Authors:
Atencio, DP
Iannuzzi, CM
Green, S
Stock, RG
Bernstein, JL
Rosenstein, BS
Citation: Dp. Atencio et al., Screening breast cancer patients for ATM mutations and polymorphisms by using denaturing high-performance liquid chromatography, ENV MOL MUT, 38(2-3), 2001, pp. 200-208
Authors:
Nag, S
Ciezki, JP
Cormack, R
Doggett, S
DeWyngaert, K
Edmundson, GK
Stock, RG
Stone, NN
Yu, Y
Zelefsky, MJ
Citation: S. Nag et al., Intraoperative planning and evaluation of permanent prostate brachytherapy: Report of the American Brachytherapy Society, INT J RAD O, 51(5), 2001, pp. 1422-1430
Authors:
Snyder, KM
Stock, RG
Hong, SM
Lo, YC
Stone, NN
Citation: Km. Snyder et al., Defining the risk of developing grade 2 proctitis following I-125 prostatebrachytherapy using a rectal dose-volume histogram analysis, INT J RAD O, 50(2), 2001, pp. 335-341
Citation: Rg. Stock et al., Penile erectile function after permanent radioactive seed implantation fortreatment of prostate cancer, J UROL, 165(2), 2001, pp. 436-439
Citation: Nn. Stone et al., Effects of neoadjuvant hormonal therapy on prostate biopsy results after I-125 and Pd-103 seed implantation, MOL UROL, 4(3), 2000, pp. 163-168
Citation: Nn. Stone et al., Biopsy results after real-time ultrasound-guided transperineal implants for stage T-1-T-2 prostate cancer, J ENDOUROL, 14(4), 2000, pp. 375-380
Authors:
Stock, RG
Stone, NN
Lo, YC
Malhado, N
Kao, J
DeWyngaert, JK
Citation: Rg. Stock et al., Postimplant dosimetry for I-125 prostate implants: Definitions and factorsaffecting outcome, INT J RAD O, 48(3), 2000, pp. 899-906
Citation: Nn. Stone et Rg. Stock, Prostate brachytherapy in patients with prostate volumes >= 50 cm(3): Dosimetic analysis of implant quality, INT J RAD O, 46(5), 2000, pp. 1199-1204
Authors:
Lehrer, S
McCurdy, LD
Stock, RG
Kornreich, R
Stone, NN
Eng, C
Citation: S. Lehrer et al., Body mass, age, and the APC I1307K allele in Ashkenazi Jewish prostate cancer patients, CANC GENET, 122(2), 2000, pp. 131-133
Authors:
Stock, RG
Stone, NN
Kao, J
Iannuzzi, C
Unger, P
Citation: Rg. Stock et al., The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy - Implications for treatment optimization, CANCER, 89(8), 2000, pp. 1829-1834
Citation: Nn. Stone et Rg. Stock, Neoadjuvant hormonal therapy improves the outcomes of patients undergoing radioactive seed implantation for localized prostate cancer, MOL UROL, 3(3), 1999, pp. 239-244
Citation: Cm. Iannuzzi et al., PSA kinetics following I-125 radioactive seed implantation in the treatment of T1-T2 prostate cancer, RADIAT ON I, 7(1), 1999, pp. 30-35
Citation: Rg. Stock et al., Does prostate brachytherapy treat the seminal vesicles? A dose-volume histogram analysis of seminal vesicles in patients undergoing combined Pd-103 prostate implantation and external beam irradiation, INT J RAD O, 45(2), 1999, pp. 385-389
Citation: S. Green et al., Rectal cancer and inflammatory bowel disease: Natural history and implications for radiation therapy, INT J RAD O, 44(4), 1999, pp. 835-840
Citation: Rg. Stock et al., Neoadjuvant androgen suppression and permanent radioactive seed implantation in the treatment of stage T-1-T-2 prostate cancer, MOL UROL, 2(3), 1998, pp. 121-126
Citation: Mb. Garnick et al., Neoadjuvant androgen suppression and permanent radioactive seed implantation in the treatment of stage T-1-T-2 prostate cancer - Discussion, MOL UROL, 2(3), 1998, pp. 127-127